RT Journal Article
SR Electronic
T1 Symptomatic, Presymptomatic, and Asymptomatic Transmission of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.08.21259871
DO 10.1101/2021.07.08.21259871
A1 Steven J. Krieg
A1 Jennifer J. Schnur
A1 Marie L. Miranda
A1 Michael E. Pfrender
A1 Nitesh V. Chawla
YR 2021
UL http://medrxiv.org/content/early/2021/07/08/2021.07.08.21259871.abstract
AB Importance Asymptomatic and presymptomatic carriers of SARS-CoV-2 are an ongoing and significant risk for community spread of the virus, especially with the majority of the world still unvaccinated and new variants emerging.Objective To quantify the presence and effects of symptom presentation (or lack thereof) on the community transmission of SARS-CoV-2.Design A cohort of 12,960 young adults participated in health reporting, contact tracing, and COVID-19 testing for 103 days between August 10 and November 20, 2020.Setting A mid-sized university campus in Indiana, United States.Participants University students, most of whom are 18-23 years old (67%) and living in congregate on-campus housing (60%). Of the 12,960 students, 1,556 (12.0%) tested positive for COVID-19 during the 103 day period. Of the positive cases, 1,198 reported sufficient health check data (7 days prior and 7 days post diagnosis) to be classified as asymptomatic or symptomatic.Main Outcome Secondary attack rate, based on presentation or absence of symptoms and type of symptoms calculated with respect to confirmed close contacts and a 14-day incubation period, varies on the type of symptom, timing of symptoms, and absence of symptoms. A quantifiable understanding of SAR on the longitudinal data of more than one thousand subjects in a university environment provides keen insights about developing strategies to respond to the continued prevalence of COVID-19 in the unvaccinated world and growth of variants.Results 32.5% of all cases reported no symptoms within a 15-day window centered on their positive test (7 days prior, the day of the positive test, and 7 days after). The secondary attack rate (SAR) of asymptomatic COVID-19 index cases was 19.1%. The SAR of symptomatic index cases was 25.4%, and while the onset timing of symptoms did not affect transmission, the presence of certain symptoms like fever, shortness of breath, and dry cough increased the SAR as high as 30.0%.Conclusions and Relevance Asymptomatic rates of transmission of SARS-CoV-2 are much higher than has been estimated in prior studies and continue to pose a significant and ongoing risk in the pandemic, especially with the prevalence of variants like the Delta variant. In addition, different symptoms are associated with varying rates of transmission, posing a significant challenge in how to diagnose or assess risk through mechanisms such as daily health checks for symptom reporting, a practice commonly in place for entry into schools, offices, restaurants, etc. Given the uncertain nature of symptoms and varied transmission rates, this study suggests a broader embrace of masking, social distancing and testing might be needed to counter the variants until higher global vaccination rates can be achieved.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was sponsored by the Lucy Family Institute for Data and Society, which conceived of the study and the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Notre Dame Human Subjects Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and code for this study are available from the corresponding author upon reasonable request.